Correction: In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia (PLoS ONE (2016) 11:12 (e0166891) DOI: 10.1371/journal.pone.0166891);In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemia

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Minagawa, Kentaro ^a   Jamil, Muhammad O ^a   Al Obaidi, Mustafa ^a   Pereboeva, Larisa ^a   Salzman, Donna ^a   Erba, Harry P ^a   Lamb, Lawrence S ^a   Bhatia, Ravi ^a   Mineishi, Shin ^a,b   Di Stasi, Antonio ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CD33 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; TUMOR NECROSIS FACTOR; ABT-737; BIPHENYL DERIVATIVE; CASP9 PROTEIN, HUMAN; CD274 PROTEIN, HUMAN; CD33 PROTEIN, HUMAN; CYCLOPHOSPHAMIDE; FUSED HETEROCYCLIC RINGS; GAMMA INTERFERON; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAFOSFAMIDE; NITROPHENOL; PIPERAZINE DERIVATIVE; SULFONAMIDE; VENETOCLAX;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CASPASE 9 GENE; CELL TRANSPLANTATION; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DYNAMICS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SUICIDE GENE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BONE MARROW CELL; CELL ENGINEERING; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; GENE VECTOR; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; NUCLEAR REPROGRAMMING; PATHOLOGY; PRIMARY CELL CULTURE; TUMOR CELL LINE;

ANTIGENS, CD274; BIPHENYL COMPOUNDS; BRIDGED BICYCLO COMPOUNDS, HETEROCYCLIC; CASPASE 9; CELL ENGINEERING; CELL LINE, TUMOR; CELL PROLIFERATION; CELLULAR REPROGRAMMING; CLINICAL TRIALS AS TOPIC; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; LEUKEMIA, MYELOID, ACUTE; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MYELOID CELLS; NITROPHENOLS; PIPERAZINES; PRIMARY CELL CULTURE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; SIALIC ACID BINDING IG-LIKE LECTIN 3; SULFONAMIDES; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84999749744     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0172640     Document Type: Erratum

References (48)

1. Thomas S, Stauss HJ, Morris EC. Molecular immunology lessons from therapeutic T-cell receptor gene transfer. Immunology. 2010; 129(2):170-7. doi: 10.1111/j.1365-2567.2009.03227.x PMID: 20561357
2. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90(2):720-4. PMID: 8421711
3. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunology today. 1997; 18(2):89-95. PMID: 9057360
4. Minagawa K, Zhou X, Mineishi S, Di Stasi A. Seatbelts in CAR therapy: How Safe Are CARS? Pharmaceuticals (Basel, Switzerland). 2015; 8(2):230-49.
5. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014; 123 (15):2343-54. doi: 10.1182/blood-2013-09-529537 PMID: 24596416
6. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, et al. Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica. 2010; 95(12):2144-52. doi: 10.3324/haematol. 2010.026310 PMID: 20713459
7. Tettamanti S, Marin V, Pizzitola I, Magnani CF, Giordano Attianese GM, Cribioli E, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. British journal of haematology. 2013; 161(3):389-401. doi: 10.1111/bjh.12282 PMID: 23432359
8. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, et al. In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia. Advances in hematology. 2012; 2012:683065. doi: 10.1155/2012/683065 PMID: 22272203
9. Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, Lassailly F, Tettamanti S, Spinelli O, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia. 2014; 28(8):1596-605. doi: 10.1038/leu.2014.62 PMID: 24504024
10. Casucci M, Nicolis di Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013; 122(20):3461-72. doi: 10.1182/blood-2013-04-493361 PMID: 24016461
11. Mardiros A, Dos Santos C, McDonald T, Brown CE, Wang X, Budde LE, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013; 122(18):3138-48. doi: 10.1182/blood-2012-12-474056 PMID: 24030378
12. Kenderian SS, Ruella M, Shestova O, Klichinsky M, Aikawa V, Morrissette JJ, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia. 2015; 29(8):1637-47. doi: 10.1038/leu.2015.52 PMID: 25721896
13. Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Molecular therapy: the journal of the American Society of Gene Therapy. 2013; 21(11):2122-9.
14. Wang QS, Wang Y, Lv HY, Han QW, Fan H, Guo B, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Molecular therapy: the journal of the American Society of Gene Therapy. 2015; 23(1):184-91.
15. McMillan SJ, Crocker PR. CD33-related sialic-acid-binding immunoglobulin-like lectins in health and disease. Carbohydrate research. 2008; 343(12):2050-6. doi: 10.1016/j.carres.2008.01.009 PMID: 18279844
16. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006; 107(3):1166-73. doi: 10.1182/blood-2005-06-2325 PMID: 16234360
17. Nakahata T, Okumura N. Cell surface antigen expression in human erythroid progenitors: erythroid and megakaryocytic markers. Leukemia & lymphoma. 1994; 13(5-6):401-9.
18. Buckley SA, Walter RB. Update on antigen-specific immunotherapy of acute myeloid leukemia. Current hematologic malignancy reports. 2015; 10(2):65-75. doi: 10.1007/s11899-015-0250-9 PMID: 25896530
19. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert opinion on biological therapy. 2008; 8(4):527-40. doi: 10.1517/14712598.8.4.527 PMID: 18352855
20. Pagano L, Fianchi L, Caira M, Rutella S, Leone G. The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene. 2007; 26(25):3679-90. doi: 10.1038/sj.onc. 1210364 PMID: 17530021
21. Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. The New England journal of medicine. 2011; 365(18):1673-83. doi: 10.1056/NEJMoa1106152 PMID: 22047558
22. Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, et al. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014; 123(25):3895-905. doi: 10.1182/blood-2014-01-551671 PMID: 24753538
23. Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015; 125(26):4103-13. doi: 10.1182/blood-2015-02-628354 PMID: 25977584
24. Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Frontiers in pharmacology. 2014; 5:235. doi: 10.3389/fphar.2014.00235 PMID: 25389405
25. Barese CN, Felizardo TC, Sellers SE, Keyvanfar K, Di Stasi A, Metzger ME, et al. Regulated apoptosis of genetically modified hematopoietic stem and progenitor cells via an inducible caspase-9 suicide gene in rhesus macaques. Stem cells (Dayton, Ohio). 2015; 33(1):91-100.
26. Zhou X, Naik S, Dakhova O, Dotti G, Heslop HE, Brenner MK. Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. Molecular therapy: the journal of the American Society of Gene Therapy. 2016; 24(4):823-31.
27. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer discovery. 2014; 4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609 PMID: 24346116
28. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clinical pharmacokinetics. 2005; 44(11):1135-64. doi: 10.2165/00003088-200544110-00003 PMID: 16231966
29. Baev DV, Krawczyk JMOD, Szegezdi E. The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells. Leukemia research reports. 2014; 3(2):79-82. doi: 10.1016/j.lrr.2014.06.001 PMID: 25379408
30. Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005; 105(11):4247-54. doi: 10.1182/blood-2004-11-4564 PMID: 15728125
31. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, et al. Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. Journal of clinical pharmacology. 2001; 41(8):870-9. PMID: 11504275
32. Cheng S, Zheng J, Zhu J, Xie C, Zhang X, Han X, et al. PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer. The International journal of biological markers. 2015; 30(4):e364-8. doi: 10.5301/jbm.5000170 PMID: 26349666
33. Wang L, Wang H, Chen H, Wang WD, Chen XQ, Geng QR, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma. Oncotarget. 2015; 6(38):41228-36. doi: 10.18632/oncotarget.5682 PMID: 26515600
34. Finkelmeier F, Canli O, Tal A, Pleli T, Trojan J, Schmidt M, et al. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. European journal of cancer (Oxford, England: 1990). 2016; 59:152-9.
35. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011; 117(17):4501-10. doi: 10.1182/blood-2010-10-310425 PMID: 21385853
36. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the PD-1/PDL1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a Tcell-induced immune escape mechanism. Leukemia. 2016; 30(2):484-91. doi: 10.1038/leu.2015.214 PMID: 26239198
37. Bhatia S. Caring for the long-term survivor after allogeneic stem cell transplantation. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2014; 2014(1):495-503.
38. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science translational medicine. 2012; 4(149):149ra18.
39. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481(7382):506-10. doi: 10.1038/nature10738 PMID: 22237025
40. Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer immunology research. 2013; 1:26-31.
41. Chang EC, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, et al. Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. Molecular therapy: the journal of the American Society of Gene Therapy. 2016; 24(4):736-45.
42. Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. The New England journal of medicine. 2016; 374(4):311-22. doi: 10.1056/NEJMoa1513257 PMID: 26639348
43. Karlsson H, Lindqvist AC, Fransson M, Paul-Wetterberg G, Nilsson B, Essand M, et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer gene therapy. 2013; 20(7):386-93. doi: 10.1038/cgt.2013.35 PMID: 23788110
44. Srinivasula SM, Hegde R, Saleh A, Datta P, Shiozaki E, Chai J, et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 2001; 410 (6824):112-6. doi: 10.1038/35065125 PMID: 11242052
45. Hu Y, Benedict MA, Wu D, Inohara N, Nunez G. Bcl-XL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(8):4386-91. PMID: 9539746
46. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, et al. Retargeting of human T cells to tumorassociated MUC1: the evolution of a chimeric antigen receptor. Journal of immunology (Baltimore, Md: 1950). 2008; 180(7):4901-9.
47. Savoldo B, Rooney CM, Di Stasi A, Abken H, Hombach A, Foster AE, et al. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood. 2007; 110(7):2620-30. doi: 10.1182/blood-2006-11-059139 PMID: 17507664
48. Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009; 113(25):6392-402. doi: 10.1182/blood-2009-03-209650 PMID: 19377047